U.S. markets close in 2 hours 53 minutes
  • S&P 500

    4,269.27
    +27.43 (+0.65%)
     
  • Dow 30

    34,208.35
    +334.11 (+0.99%)
     
  • Nasdaq

    14,378.10
    +106.37 (+0.75%)
     
  • Russell 2000

    2,324.35
    +20.88 (+0.91%)
     
  • Crude Oil

    73.09
    +0.01 (+0.01%)
     
  • Gold

    1,776.90
    -6.50 (-0.36%)
     
  • Silver

    26.08
    -0.04 (-0.14%)
     
  • EUR/USD

    1.1935
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.4940
    +0.0070 (+0.47%)
     
  • GBP/USD

    1.3922
    -0.0042 (-0.30%)
     
  • USD/JPY

    110.8610
    -0.1010 (-0.09%)
     
  • BTC-USD

    34,890.98
    +1,190.46 (+3.53%)
     
  • CMC Crypto 200

    838.03
    +51.41 (+6.54%)
     
  • FTSE 100

    7,109.97
    +35.91 (+0.51%)
     
  • Nikkei 225

    28,875.23
    +0.34 (+0.00%)
     

Eagle Pharmaceuticals to Present at the 2021 RBC Capital Markets Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the 2021 RBC Capital Markets Global Healthcare Conference as follows:

Date:

Tuesday, May 18, 2021

Time:

1:20 p.m. Eastern Time

Webcast:

https://event.on24.com/wcc/r/3173733/CEA9B803E5C77274A4417D4FE2A0EAB0

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.eagleus.com, under the Investors Section.

About Eagle Pharmaceuticals, Inc.

Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include RYANODEX®, BENDEKA®, BELRAPZO®, and its oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle’s website at www.eagleus.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210511006203/en/

Contacts

Investor Relations for Eagle Pharmaceuticals, Inc.:
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com